Non Hodgkin Lymphoma Clinical Trial

Clinical Trial Finder Non Hodgkin Lymphoma Trials

Study of Nivolumab in Subjects With Relapsed or Refractory Follicular Lymphoma (FL) (CheckMate 140)

See Locations Near You

Summary

The purpose of this study is to assess the clinical benefit of Nivolumab, as measured by independent radiologic review committee (IRRC)-assessed objective response rate (ORR) in subjects with FL lymphoma who have failed therapy with both CD20 antibody and an alkylating agent.

View Eligibility Criteria

Eligibility Criteria

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

Grade 1, 2, or 3a FL without pathologic evidence of transformation
Male and female, ages 18 and above, with relapsed or refractory FL lymphoma after > or =2 prior treatment lines; each of the 2 prior treatment lines must include at least CD20 antibody and/or an alkylating agent
Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0-1

Exclusion Criteria:

Known central nervous system lymphoma
History of interstitial lung disease
Subjects with active, known or suspected autoimmune disease
Prior allogeneic stem cell transplant
Prior autologous stem cell transplant ≤12 weeks prior to first dose of study drug

Study is for people with:

Non Hodgkin Lymphoma

Phase:

Phase 2

Estimated Enrollment:

116

Study ID:

NCT02038946

Recruitment Status:

Completed

Sponsor:

Bristol-Myers Squibb

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 41 Locations for this study

See Locations Near You

Mayo Clinic Arizona
Phoenix Arizona, 85054, United States
Division Of Hematology & Oncology Ctr. For Health Sciences
Los Angeles California, 90095, United States
Winship Cancer Institute.
Atlanta Georgia, 30322, United States
Beth Israel Deaconess Medical Center (BIDMC)
Boston Massachusetts, 02215, United States
Dana Farber Cancer Institute
Boston Massachusetts, 02215, United States
Massachusetts General Hospital
Boston Massachusetts, 02215, United States
Mayo Clinic
Rochester Minnesota, 55905, United States
Weill Cornell Medical College
New York New York, 10021, United States
Duke University Medical Center
Durham North Carolina, 27710, United States
Vanderbilt University Medical Center
Nashville Tennessee, 37232, United States
MD Anderson Cancer Center
Houston Texas, 77030, United States
Huntsman Cancer Institute
Salt Lake City Utah, 84112, United States
Local Institution
Woodville South Australia, 5011, Australia
Local Institution
Parkville Victoria, 3050, Australia
Local Institution
B-leuven , 3000, Belgium
Local Institution
Bruxelles , 1200, Belgium
Local Institution
Gent , 9000, Belgium
Jewish General Hospital
Montreal Quebec, H3T 1, Canada
CISSS du Bas-Saint-Laurent Hopital Regional de Rimouski
Rimouski Quebec, G5L 5, Canada
Local Institution
Creteil , 94010, France
Local Institution
Montpellier Cedex 05 , 34295, France
Local Institution
Pierre Benite Cedex , 69495, France
Local Institution
Rennes , 35033, France
Universitaetsklinikum Essen
Essen , 45147, Germany
Universitaetsklinikum d. Saarlandes
Homburg , 66424, Germany
Universitaetsklinikum Des Saarlandes
Homburg , 66424, Germany
Local Institution
Regensburg , 93053, Germany
Universitaetsklinikum Ulm
Ulm , 89081, Germany
Local Institution
Bergamo , 24127, Italy
Local Institution
Bologna , 40138, Italy
Local Institution
Milano , 20133, Italy
Local Institution
Napoli , 80131, Italy
Local Institution
Roma , 00161, Italy
Local Institution
Oslo , 0424, Norway
Local Institution
Singapore , 16986, Singapore
Local Institution
Singapore , 30843, Singapore
Hospital Duran I Reynals
Hospitalet Llobregat- Barcelona , 9908, Spain
Local Institution
Madrid , 28009, Spain
Hospital Universitario La Paz
Madrid , 28046, Spain
Local Institution
Salamanca , 37007, Spain
Local Institution
Gothenberg , 413 4, Sweden
Local Institution
Gothenburg , 413 4, Sweden
Local Institution
Southampton Hampshire, SO16 , United Kingdom
Local Institution
Withington Manchester, M20 4, United Kingdom
Local Institution
Sutton Surrey, SM2 5, United Kingdom
Load More

How clear is this clinincal trial information?

Study is for people with:

Non Hodgkin Lymphoma

Phase:

Phase 2

Estimated Enrollment:

116

Study ID:

NCT02038946

Recruitment Status:

Completed

Sponsor:


Bristol-Myers Squibb

How clear is this clinincal trial information?

Clinical Trial Resources

Why I’d Choose a Clinical Trial For Myself
Clinical Trials Can be Life-Saving for Some
Clinical Trials Test State-of-the-Art Cancer Treatments
×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider